

In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pharmaceutical composition, comprising 0.5 ng to 20 µg desmopressin and a pharmaceutically acceptable carrier, wherein said pharmaceutical composition establishes a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum.

2. (Canceled)

3. (Original) The pharmaceutical composition of claim 1, wherein said pharmaceutical composition comprises from about 0.05 µg to about 10 µg desmopressin.

4. (Currently Amended) The pharmaceutical composition of claim 1, wherein said pharmaceutical composition comprises from about 0.1 µg to about 2 µg ~~20 µg~~ desmopressin.

5. (Original) The pharmaceutical composition of claim 1, wherein said pharmaceutical composition is adapted for intravenous, subcutaneous, transmucosal, transdermal, or intradermal delivery.

6. (Original) The pharmaceutical composition of claim 1, wherein said pharmaceutical composition is in the form of an orodispersible solid.

7. (Original) The pharmaceutical composition of claim 1, further comprising an open matrix network, said open matrix network comprising a water-soluble or water-dispersible carrier material that is inert towards desmopressin.

8. (Cancel)

9. (Currently Amended) The pharmaceutical composition of claim 1 ~~claim 8~~, wherein said steady plasma/serum desmopressin concentration is in the range of from about 0.5 picograms desmopressin per mL plasma/serum to about 5.0 picogram desmopressin per mL plasma/serum.

Claims 10. - 13. (Canceled)

14. (Currently Amended) An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said pharmaceutical composition is therapeutically effective for treating or preventing hemophilia, Von Willebrand's Disease, incontinence, primary nocturnal enuresis (PNE), nocturia, or central diabetes insipidus, and wherein said packaging material comprises a label which indicates that the pharmaceutical composition can be used for treating or preventing hemophilia, Von Willebrand's Disease, incontinence, primary nocturnal enuresis (PNE), nocturia, or central diabetes insipidus, and wherein said pharmaceutical composition comprises 0.5 ng to 20 µg desmopressin and a

pharmaceutically acceptable carrier, and wherein said pharmaceutical composition establishes a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum.

15. (Currently Amended) A method of treating or preventing a disease or condition which is treatable or preventable by desmopressin, said method comprising administering to a patient ~~a daily dose of a therapeutically effective amount of a~~ pharmaceutical composition comprising 0.5 ng to 20 µg desmopressin and a pharmaceutically acceptable carrier, said pharmaceutical composition establishing a steady plasma/serum desmopressin concentration in said patient in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum.

16. (Original) The method of claim 15, wherein said disease or condition is selected from the group consisting of hemophilia, Von Willebrand's Disease, incontinence, primary nocturnal enuresis (PNE), nocturia, or central diabetes insipidus.

17. (Currently Amended) A method inducing an antidiuretic effect in a patient, comprising the step of administering to a patient ~~a daily dose of a therapeutically effective amount of a~~ pharmaceutical composition comprising 0.5 ng to 20 µg desmopressin and a pharmaceutically acceptable carrier, said pharmaceutical composition establishing a steady plasma/serum desmopressin concentration in said patient in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 1.0 picogram desmopressin per mL plasma/serum.

18. (Original) The method of claim 17, wherein said patient is suffering from a disease selected from the group consisting of Von Willebrand's Disease, incontinence, primary nocturnal enuresis (PNE), nocturia, or central diabetes insipidus.

19. (New) The method of claim 15, wherein said pharmaceutical composition comprises from about 0.05 µg to about 10 µg desmopressin.

20. (New) The method of claim 15, wherein said pharmaceutical composition comprises from about 0.1 µg to about 2 µg desmopressin.

21. (New) The method of claim 15, wherein said pharmaceutical composition is adapted for intravenous, subcutaneous, transmucosal, transdermal, or intradermal delivery.

22. (New) The method of claim 15, wherein said steady plasma/serum desmopressin concentration is in the range of from about 0.5 picograms desmopressin per mL plasma/serum to about 5.0 picogram desmopressin per mL plasma/serum.

23. (New) The method of claim 17, wherein said pharmaceutical composition comprises from about 0.05 µg to about 10 µg desmopressin.

24. (New) The method of claim 17, wherein said pharmaceutical composition comprises from about 0.1 µg to about 2 µg desmopressin.

25. (New) The method of claim 17, wherein said pharmaceutical composition is adapted for intravenous, subcutaneous, transmucosal, transdermal, or intradermal delivery.

26. (New) The method of claim 17, wherein said steady plasma/serum desmopressin concentration is in the range of from about 0.5 picograms desmopressin per mL plasma/serum to about 5.0 picogram desmopressin per mL plasma/serum.